Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Jan 16;16(1):213–233. doi: 10.1017/S1461145711001933

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© CINP 2012

The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/2.5/>. The written permission of Cambridge University Press must be obtained for commercial re-use.

PMC Copyright notice

Fig. 4. — The selective P2rx7 antagonist Brilliant Blue G (BBG) exhibits antidepressant-like activity in the tail suspension test (TST), decreases amphetamine-induced hyperactivity and elevates norepinephrine (NE) level in the amygdala in P2rx7^+/+, but not P2rx7^−/− mice. (a) The effect of acute BBG treatment on basal immobility in P2rx7^+/+ mice (n = 13–15). (b) Effect of sub-acute, 1-wk treatment with BBG on basal immobility in P2rx7^+/+ mice. Mice were treated with BBG for 7 d with the daily doses indicated on the abscissa or with saline (Sal) and then submitted to the TST (n = 13–15, * p < 0.05 vs. SAL, one-way analysis of variance (ANOVA), followed by Dunnett's test). (c) Citalopram (Cit; 15 mg/kg), the potent selective serotonin reuptake inhibitor antidepressant, decreased basal immobility in the TST in P2rx7^+/+mice (n = 11/group, * p < 0.05 vs. Sal, Student's t test). (d) Effect of 1-wk daily treatment with BBG (25–50 mg/kg i.p.) or Sal on amphetamine induced hyperactivity in P2rx7^+/+mice. (n = 10–12/group, ** p < 0.001 vs. Sal, one-way ANOVA followed by Dunnett's test). Citalopram and BBG were administered i.p. 30 min before testing at the doses (mg/kg) indicated on the abscissa. Sal-treated mice were injected with an equal volume of Sal. (e) Effect of sub-acute, 1-wk treatment with BBG (50 mg/kg i.p.) on basal immobility in P2rx7^−/− mice. Mice were treated with BBG for 7 d or with Sal and then submitted to the TST (n = 8–10/group). (f) Effect of 1-wk daily treatment with BBG (50 mg/kg i.p.) or Sal on amphetamine-induced hyperactivity in P2rx7^−/− mice (n = 10/group). Note that the basal immobility (e) and amphetamine-induced hyperactivity (f) is lower in Sal-treated P2rx7^−/− mice than in Sal-treated P2rx7^+/+ mice. (g) Sub-acute, 1-wk treatment with BBG (50 mg/kg i.p.) elevates NE, but not 5-HT levels in the amygdala in P2rx7^+/+ mice, when compared to Sal-treated mice. Tissue content of NE and 5-HT were analysed by high performance liquid chromatography and are expressed in pmol/mg protein, n = 11–12, ** p < 0.01, Student's t test.